- Home
- PDD vs GILD Comparison
PDD vs GILD Comparison
Compare PDD & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDD | GILD |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.9B | 168.6B |
| IPO Year | 2018 | 2002 |
Fundamental Metrics
Financial Performance| Metric | PDD | GILD |
|---|---|---|
| Price | $95.58 | $132.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 18 |
| Target Price | $139.22 | ★ $148.39 |
| AVG Volume (30 Days) | ★ 5.9M | 4.9M |
| Earning Date | 05-26-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.55% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | N/A | ★ 1.61 |
| Revenue | N/A | ★ $24,689,000,000.00 |
| Revenue This Year | $15.35 | $4.68 |
| Revenue Next Year | $12.63 | $6.04 |
| P/E Ratio | ★ $10.63 | $82.63 |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $95.24 | $100.23 |
| 52 Week High | $139.41 | $157.29 |
Technical Indicators
Market Signals| Indicator | PDD | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 42.59 | 43.99 |
| Support Level | N/A | $116.55 |
| Resistance Level | $106.47 | $142.33 |
| Average True Range (ATR) | 2.74 | 3.21 |
| MACD | -0.19 | 0.40 |
| Stochastic Oscillator | 3.35 | 43.97 |
Price Performance
Historical ComparisonAbout PDD PDD Holdings Inc.
PDD Holdings operates commerce businesses in over 80 countries globally. Its main operations are Pinduoduo, a social commerce platform in China, and Temu, a global e-commerce marketplace. PDD also has a community group purchase business in China. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).